Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care
Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system. "Waste in the system is created by ineffective technology and claims processing that is very cumbersome for both payers and providers," says Dr. Feinberg.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen-deprivation therapy and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
During this opening segment of a one-on-one interview series, Peter Salgo, MD, discusses emerging diagnostic and prognostic biomarkers in prostate cancer with Ira M. Klein, MD, MBA, FACP. Dr Klein discusses how results of ongoing trials will be useful to help identify biomarkers to help providers track disease progression.
The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.
Clinical trials are critical for pushing the oncology field forward, but there is a need for not only more patients to participate in clinical trials, but for a more diverse population, said Howard K. Kaufman, MD, FACS.
California advocates worry that having half its children in Medi-Cal will mean poor access to care. But the real issue may be the growing number of poor children nationwide and the overall effect on Medicaid.
Reports say NIH would receive funds to collect DNA from 1 million volunteers, the National Cancer Institute would get research funds, and FDA would get support to regulate molecular diagnostic tests. The plans need funding from Congress.